Stock Analysis on Net
Stock Analysis on Net

Merck & Co. Inc. (NYSE:MRK)

$24.99

Analysis of Solvency Ratios
Quarterly Data

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check

Solvency Ratios (Summary)

Merck & Co. Inc., solvency ratios (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Debt Ratios
Debt to equity
Debt to capital
Debt to assets
Financial leverage

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The solvency profile exhibits a period of relative stability from early 2022 through 2024, followed by a distinct upward trend in leverage and debt dependency throughout 2025 and the first half of 2026.

Debt to Equity Ratio
An initial downward trend is observed from March 2022 (0.78) to a low of 0.66 in March 2023. This is followed by a period of volatility and moderate elevation throughout 2023 and 2024, with values oscillating between 0.80 and 0.95. A significant acceleration in the ratio begins in September 2025, culminating in a peak of 1.29 by June 2026, indicating a shift toward a higher proportion of debt relative to shareholders' equity.
Debt to Capital Ratio
The ratio remained relatively contained between 0.40 and 0.49 for the majority of the period between March 2022 and December 2024. Starting in September 2025, a consistent quarterly increase is noted, moving from 0.44 to 0.56 by June 2026, suggesting that debt has become a larger component of the total capital structure.
Debt to Assets Ratio
A stable baseline was maintained between 0.28 and 0.35 from March 2022 through December 2024. A gradual increase is observed starting in September 2025 (0.32), with the ratio climbing steadily to reach 0.42 by June 2026. This indicates that a growing percentage of the organization's assets are financed through debt.
Financial Leverage
The financial leverage ratio shows fluctuations between 2.30 and 2.84 throughout 2022 and 2023, before stabilizing between 2.38 and 2.64 in 2024. A clear upward trajectory is evident from March 2025 (2.38), with the ratio increasing each subsequent quarter to reach its highest point of 3.10 in June 2026.

Overall, the metrics demonstrate a synchronized increase in solvency risk toward the end of the observed period. The simultaneous rise in all four ratios from 2025 onward suggests a strategic or operational increase in borrowing and a higher reliance on debt financing to support the balance sheet.


Debt Ratios


Debt to Equity

Merck & Co. Inc., debt to equity calculation (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Loans payable and current portion of long-term debt
Long-term debt, excluding current portion
Total debt
 
Total Merck & Co., Inc. stockholders’ equity
Solvency Ratio
Debt to equity1
Benchmarks
Debt to Equity, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Debt to equity = Total debt ÷ Total Merck & Co., Inc. stockholders’ equity
= ÷ =

2 Click competitor name to see calculations.


An analysis of the solvency profile reveals a significant escalation in leverage over the observed period, characterized by a transition from a conservative debt-to-equity position to a more aggressive capital structure. The debt-to-equity ratio exhibited an initial downward trend, reaching a period low of 0.66 in March 2023, before entering a phase of volatility and a subsequent sharp increase toward the end of the series.

Total Debt Trajectory
Total debt remained relatively stable between March 2022 and December 2024, fluctuating primarily between 30.4 billion and 38.1 billion USD. However, a substantial upward trend emerged starting in September 2025, with debt levels rising from 41.3 billion USD to a peak of 53.9 billion USD by June 2026. This represents a marked increase in borrowing during the final six quarters of the analysis.
Stockholders' Equity Fluctuations
Equity showed a general growth trend from March 2022 through December 2024, increasing from 40.8 billion USD to 48.3 billion USD, despite a temporary contraction in June 2023. Equity peaked at 52.6 billion USD in December 2025. A notable decline is observed in the first half of 2026, where equity dropped to 41.9 billion USD, contributing to the acceleration of the solvency ratio.
Debt to Equity Ratio Dynamics
The debt-to-equity ratio experienced three distinct phases. First, a deleveraging phase occurred between March 2022 and March 2023, where the ratio declined from 0.78 to 0.66. Second, a period of instability followed from June 2023 to June 2025, with the ratio oscillating between 0.72 and 0.95. Third, a rapid escalation began in September 2025, with the ratio climbing from 0.80 to 1.29 by June 2026. The crossing of the 1.0 threshold in March 2026 indicates a shift where total debt exceeded total stockholders' equity.

The convergence of rising total debt and declining stockholders' equity in the final two quarters of the analysis resulted in a steep increase in the debt-to-equity ratio. This suggests a significant shift in the company's financing strategy or an increase in liabilities that outpaced equity growth, ending the period at the highest leverage level recorded since March 2022.


Debt to Capital

Merck & Co. Inc., debt to capital calculation (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Loans payable and current portion of long-term debt
Long-term debt, excluding current portion
Total debt
Total Merck & Co., Inc. stockholders’ equity
Total capital
Solvency Ratio
Debt to capital1
Benchmarks
Debt to Capital, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =

2 Click competitor name to see calculations.


The solvency profile of the organization exhibits a general trend of increasing leverage over the analyzed period, characterized by a significant rise in total debt and a corresponding increase in the debt-to-capital ratio toward the end of the timeframe.

Total Debt Trends
Total debt remained relatively stable between March 2022 and March 2023, fluctuating around the $30 billion to $31 billion range. A notable increase occurred in June 2023, where debt rose to $36.91 billion. Following a period of moderate volatility between 2023 and 2024, a sharp acceleration in borrowing is observed starting in September 2025, with total debt climbing from $41.37 billion to $53.91 billion by June 2026.
Total Capital Movements
Total capital demonstrated a steady upward trajectory for much of the period, growing from $72.68 billion in March 2022 to a peak of $101.95 billion in December 2025. This growth suggests an expansion of the overall capital base, although a contraction is noted in the first quarter of 2026, where capital decreased to $94.99 billion before stabilizing at $95.84 billion in June 2026.
Debt to Capital Ratio Analysis
The debt-to-capital ratio initially declined from 0.44 in March 2022 to a low of 0.40 by March 2023, indicating a temporary reduction in financial leverage. The ratio then shifted upward, stabilizing between 0.44 and 0.48 throughout 2023 and 2024. A significant escalation in leverage is evident in 2026, as the ratio rose from 0.42 in June 2025 to 0.56 by June 2026, representing the highest level of leverage in the reported period.

The synchronization of rising total debt and a peaking debt-to-capital ratio in the final quarters suggests a strategic shift toward higher leverage, as the growth in debt began to outpace the growth in total capital during the 2025-2026 window.


Debt to Assets

Merck & Co. Inc., debt to assets calculation (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Loans payable and current portion of long-term debt
Long-term debt, excluding current portion
Total debt
 
Total assets
Solvency Ratio
Debt to assets1
Benchmarks
Debt to Assets, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =

2 Click competitor name to see calculations.


The solvency profile exhibits a transition from a stable leverage position to a more aggressive debt-funded structure over the analyzed period. While assets grew moderately, the acceleration of total debt in the later quarters led to a notable increase in the company's overall leverage.

Total Debt Trajectory
Between March 2022 and December 2022, total debt remained relatively stable, fluctuating around 31 billion USD. A primary increase occurred in June 2023, with debt rising to 36.9 billion USD. This upward trend accelerated sharply in the final stages of the period, with total debt escalating from 35.4 billion USD in June 2025 to 53.9 billion USD by June 2026.
Total Asset Evolution
Assets remained largely consistent between 104 billion USD and 117 billion USD from 2022 through 2023. A growth phase emerged in 2024, with total assets peaking at 136.9 billion USD in December 2025 before adjusting to 129.8 billion USD by June 2026. Despite this growth, the expansion of the asset base was insufficient to offset the rapid increase in debt incurred during 2025 and 2026.
Debt to Assets Ratio Progression
The debt to assets ratio was maintained within a tight range of 0.28 to 0.35 from March 2022 through March 2025, suggesting a disciplined approach to solvency. However, a distinct upward shift is observed starting in September 2025, as the ratio climbed from 0.32 to 0.42 by June 2026. This progression reflects a significant increase in financial leverage, with debt representing a larger proportion of total assets by the end of the analyzed period.

Financial Leverage

Merck & Co. Inc., financial leverage calculation (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Total assets
Total Merck & Co., Inc. stockholders’ equity
Solvency Ratio
Financial leverage1
Benchmarks
Financial Leverage, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Financial leverage = Total assets ÷ Total Merck & Co., Inc. stockholders’ equity
= ÷ =

2 Click competitor name to see calculations.


The financial leverage of the organization exhibits a cyclical pattern over the observed period, characterized by an initial phase of deleveraging followed by a period of volatility and a significant increase in the final quarters.

Asset Base Evolution
Total assets maintained a relatively stable trajectory between March 2022 and March 2024, fluctuating generally between 104 billion and 109 billion. A pronounced expansion began in June 2024, with assets climbing to a peak of 136.87 billion by December 2025. This growth suggests a substantial expansion of the company's resource base, which subsequently stabilized around 129 billion in the first half of 2026.
Equity Dynamics
Stockholders' equity displayed significant fluctuations throughout the period. An initial growth phase peaked in March 2023 at 46.83 billion, followed by a volatile sequence in 2023. Equity then entered a steady recovery and growth phase, reaching its maximum value of 52.61 billion in December 2025. However, a sharp contraction occurred in the first half of 2026, with equity falling to 41.93 billion by June 2026.
Financial Leverage Ratio Analysis
The financial leverage ratio initially declined from 2.61 in March 2022 to a low of 2.30 in March 2023, indicating a strategic reduction in the proportion of debt relative to equity. This was followed by a period of instability throughout 2023, where the ratio reached 2.84 by December. Between March 2024 and December 2025, the ratio remained relatively contained, oscillating between 2.38 and 2.60. A notable upward shift occurred in 2026, with the ratio climbing to 3.10 by June 2026, representing the highest leverage level in the analyzed timeframe.
Solvency Implications
The surge in financial leverage to 3.10 in mid-2026 is primarily driven by the contraction of stockholders' equity while the asset base remained high. This divergence indicates an increased reliance on external liabilities or a significant reduction in equity capital, thereby elevating the company's financial risk profile toward the conclusion of the reporting period.